RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...
FY2024 EPS Estimates for Illumina Raised by Leerink Partnrs
Stock analysts at Leerink Partnrs increased their FY2024 earnings estimates for Illumina in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda ...